Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on January 31st, 2012% (Genome.gov)
The Canadian government opened a matching grant competition for research proposals on personalized medicine. The call seeks research proposals that can take treatments from “one size fits all” to more precise treatments and interventions addressing specific characteristics of the individual, made possible by new diagnostic technologies that look at patients’ unique genetic . . . → Read More: Canadian Govt Opens Call for Personalized Medicines R&D
By Alan, on January 31st, 2012% (Wikimedia Commons)
The National Foundation for Cancer Research (NFCR) has awarded a $600,000 grant to the Translational Genomics Research Institute (TGen) in Phoenix and the University of Arizona in Tucson for the study of targeted cancer therapies. The three-year grant will enable TGen and the university to continue its NFCR Center for Targeted . . . → Read More: $600K Foundation Grant to Fund Cancer Genomics Research
By Alan, on January 31st, 2012% WaterShed (University of Maryland)
The electric utility company Pepco says it will purchase the WaterShed house that won the 2011 Solar Decathlon contest in October. The house was built by faculty and students at the University of Maryland in College Park, its current location.
The 2011 Solar Decathlon pitted 20 teams representing institutions . . . → Read More: Maryland Utility to Purchase Solar Contest Winning House
By Alan, on January 31st, 2012% (America.gov)
In London yesterday, the Bill & Melinda Gates Foundation, 13 pharmaceutical companies, three governments, the World Bank and global health agencies announced a new plan to eliminate or control 10 neglected tropical diseases (NTDs) by 2020. The effort announced at an event at the Royal College of Physicians is aimed at 1.4 . . . → Read More: Pharmas, Foundations, Agencies Partner on Tropical Diseases
By Alan, on January 30th, 2012% (NOAA)
The Food and Drug Administration today approved the drug vismodegib to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug, marketed under the brand name Erivedge by Genentech in South San Francisco, is intended for use in patients with locally advanced basal cell cancer who . . . → Read More: FDA Approves Genentech Skin Cancer Drug
By Alan, on January 30th, 2012% David McGahon taking test measurements of "smart painted" surface (University of Strathclyde)
Researcher engineers at University of Strathclyde in Glasgow, U.K. have developed a type of paint that can help detect early signs of structural damage in bridges or buildings. Because this “smart paint” can be applied like any other paint and requires . . . → Read More: Nanotech Paint Devised to Monitor for Structural Damage
By Alan, on January 30th, 2012% Venture capital declined 14 percent and number of deals dropped 19 percent for European companies in 2011 compared to 2010, with €4.4 billion ($US 5.8 billion) going into 1,012 deals. Industries based on scientific discoveries were among those suffering double-digit percentage declines from the previous year.
Dow Jones VentureSource that compiled the data says it . . . → Read More: Venture Investment for European Companies Drops in 2011
By Alan, on January 30th, 2012% (BLS.gov)
ConforMIS Inc. in Burlington, Massachusetts, a developer of customized knee-replacement implant technology, has raised $89 million in a series E round of funding, the fifth investment cycle after start up. The privately held company says the investments were made by private equity funds, led by AGC Equity Partners and Axel Johnson Inc., . . . → Read More: Knee Replacement Maker Lands $89M Series E Financing
By Alan, on January 27th, 2012% Cross-section of kidney (National Library of Medicine)
The Food and Drug Administration today approved the drug axitinib to treat patients with renal cell carcinoma, a form of advanced kidney cancer, who have not responded to another drug for this type of cancer. The drug is made by Pfizer Inc. in New York and . . . → Read More: FDA Approves Pfizer Drug for Advanced Kidney Cancer
By Alan, on January 27th, 2012% Central Square subway station, Cambridge, Mass.
The Experiment Fund, a joint venture of Harvard University’s engineering school and venture capital company New Enterprise Associates (NEA), opened today in Cambridge, Massachusetts. The fund plans to support technology-based student start-ups in Cambridge and companies begun elsewhere by former students.
The venture expects to support companies . . . → Read More: VC Company, Harvard Start Seed-Stage Fund
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.